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estimates. Results: Treatment with pegylated interferon alfa-2a was associated 
with lower total costs. The estimated budget savings varied from 20,907.97 RUB 
to 104,366.07 RUB per one patient. CERs for pegylated interferon alfa-2a were 
less than that for pegylated interferon alfa-2b in all patient subgroups. The low-
est CER was observed for patients with genotype 2 received pegylated interferon 
alfa-2a (240,789.70 RUB per one patient with SVR) and the highest CER – for cir-
rhotic patients with genotype 1 received pegylated interferon alfa-2b (1,879,694.72 
RUB per one patient with SVR). The analysis of the IRDU showed, that inefficient 
budget expenses associated with pegylated interferon alfa-2b treatment may reach 
58,770.84 RUB per one patient infected with HCV-genotypes 1/4. SAs demonstrated 
that results were robust to changes in the drug costs. ConClusions: The present 
study has demonstrated that administration of pegylated interferon alfa-2a has 
the better pharmacoeconomic profile in the treatment of Russian patients with 
chronic hepatitis C.
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objeCtives: To estimate the cost of treatment discontinuation due to label stopping 
(futility) rules of telaprevir (TVR) and boceprevir (BOC) triple therapy in Brazilian 
public (SUS) and private health care system (SS). Methods: Treatment costs con-
sidered drug acquisition costs from a public and private payer perspective in Brazil. 
Stopping rules (SR) were defined according to the label of each drug. For TVR the SR 
were defined at week4 (SR WK4) and at week 12 (SR WK12) as viral load (VL) > 1.000 
IU/ML. For BOC, SR were defined at week 12 (SR WK12) as VL > 100 UI/mL and at week 
24 (SR WK24) as detectable VL. Patients eligible for the SR were gathered for naïve 
and experienced patients from the respective phase 3 trials. As data for SR WK24 
was not published for BOC in naïve patients it was assumed to be the same as SR 
WK12 and a deterministic sensitivity analysis was carried out. Results: Under 
the SUS perspective, the average cost of naïve patients interrupting treatment with 
TVR was R$ 670 compared to an average cost of R$ 3.396 per interrupted treatment 
with BOC, and for treatment experienced patients, TVR had an average cost of R$ 
352 compared to an average cost of R$ 3.041 for BOC per patient meeting the SR. 
Under the SS perspective, TVR had an average cost of R$ 1.433 per interrupted naïve 
treatment and R$ 753 per interrupted treatment in experienced patients and BOC 
had an average treatment cost of R$ 8.305 per naïve patient interrupting treatment 
and R$ 4.753 per interrupted treatment in experienced patients. ConClusions: 
BOC had higher costs associated with treatment futility when compared to TVR, 
especially in treatment experienced patients, in both the public and private health 
care systems in Brazil.
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objeCtives: Currently, 23 thousand people (registered) are suffering from Hepatitis 
C in Germany (more 60% genotype 1). TThe licensing of direct-acting antivirals 
heralds a new era in the treatment of hepatitis C virus (HCV) genotype 1. Clinical 
studies showed a significant increase in sustained virological response rates from 
38-46% to 63-79%. This study was to evaluate the cost-effectiveness of newly intro-
duced triple therapy with Telaprevir (TVR+PR) compared to dual therapy (PR) for the 
treatment of genotype 1 hepatitis C virus (HCV) infection in previously untreated 
patients. Methods: A systematic literature review identified relevant studies. A 
Bayesian mixed treatment comparison model was fitted for each patient popu-
lation. Previously published economic Markov model comparing triple therapy 
(TVR + PR) and dual therapy (PR) has been adjusted for the Kazakhstan context of 
health care (payer perspective). Clinical outcomes and dose were taken from the 
phase ADVANCE-3 trial. Other parameters of the model - including utilities - were 
adapted from Kazakhstan or if not available from the international literature after 
an extensive search of the literature. Drug costs were taken from the list of drugs 
Kazakhstan. All costs were inflated to 2012 goda.Skidka of 3% and the horizon of 
life were considered. Results: Base-case analysis shows that the triple treatment 
(TVR + PR) than dual therapy (PR) leads to increased costs, and the best results. The 
results were robust when analyzing multiple sensitivity. The discount rate seemed to 
have a great impact. ConClusions: Telaprevir triple therapy for previously treated 
patients with HCV-genotype 1, more efficient than the dual therapy, but it leads to 
increased costs (in particular, the cost of medications).
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objeCtives: To estimate the costs of once-daily fixed dose combination (FDC) 
abacavir/lamivudine (ABC/3TC) compared with twice-daily combination of its 
individual components (ABC+3TC) and twice-daily FDC zidovudine/lamivudine 
(ZDV/3TC) in efavirenz (EFV)-based regimens for treatment-naïve adults with HIV 
infection in Russia. Methods: An Excel based model was developed to estimate the 
costs over 48- and 96-week time horizon for three compared regimens. Probabilities 
of switching to alternative and 2d line therapy due to low adherence and side effects 
were estimated for each regimen based on literature search. Costs of antiretroviral 
determinant of wasted doses was the number of children arriving. Depending 
on whether the clinic setting was urban/ rural, or outreach/fixed center, median 
session sizes varied between 5-13 children. Vaccine wastage added significant 
cost due to variations in session size even when modeled using a low multidose 
vial strategy. For instance, open vial waste from pneumococcal delivered in 5-dose 
presentation contributed $20MM in waste to Ugandan 10-year program costs. 
Results for each country and the impact session size distributions will be pre-
sented. ConClusions: Our analysis of field data confirmed significant session 
size variation within/across country immunization settings. Given challenges in 
mandating session sizes, pressures on vaccine budgets and high value of vaccine 
delivery, policy makers must consider new solutions to reduce the impact of waste 
on total program costs.
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objeCtives: To estimate the budget impact of the inclusion of ceftaroline com-
pared to linezolid or vancomycin on the top of complicated skin and soft tissues 
infections treatment scheme with antimicrobials according to Russian health care 
system. Methods: The budget impact analysis was conducted. Direct expenses 
associated with complicated skin and soft tissues infections and resulting follow-up 
costs were calculated using general tariff agreement of Russian obligatory insurance 
system and official national statistics. For reference, accepted exchange rate was 1 
EUR = 40 RUB. Results: Ceftaroline inclusion into the standard complicated skin 
and soft tissues infections therapy provided cost saving benefits compared with 
inclusion of linezolid or vancomycin in the complicated skin and soft tissues infec-
tions standard therapy scheme. Total health care costs of complicated skin and soft 
tissues infections therapy were approximately 77 997 RUB (1 950 EUR) per patient 
in ceftaroline group (therapy duration – 9 days), 78 816 RUB (1 970 EUR) per patient 
in vancomycin group (therapy duration – 10 days) and 117 893 RUB (2 947 EUR) per 
patient in linezolid group (therapy duration – 12 days). Treatment of complicated 
skin and soft tissues infections using standard therapy with ceftaroline inclusion 
compared to one with vancomycin or linezolid leads to cost savings of 819 RUB (20 
EUR) or 39 896 RUB (997 EUR) per patient, respectively. ConClusions: The results 
of budget impact analysis illustrate that including ceftaroline into the standard 
therapy of complicated skin and soft tissues infections in comparison with vanco-
mycin or linezolid has potential to reduce Russian health care system total costs 
for complicated skin and soft tissues infections treatment.
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objeCtives: To estimate the cost impact to the NHS of switching from vial and 
syringe (V&S) to pre-filled syringe (PFS) administration of the ‘5-in-1’ vaccine for 
diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b. Methods: 
A model was developed to estimate the cost impact of the switch in children less 
than 2 years old. Vaccines supplied were assumed to reach three destinations: 
administered (an estimate of 785,320 primary courses); opened and not adminis-
tered (assumed to account for 7% of V&S and 0% of PFS supplied); or not opened 
by the expiry date (assumed to account for 0% of supply). All vaccines accrued 
acquisition and storage costs. PFS has bulkier packaging, leading to higher stor-
age costs. Administered vaccines incurred costs for staff time, consumables (only 
required for V&S) and potential needlestick injuries (assumed not to occur with 
PFS). As prices paid for vaccines by the NHS are not disclosed, the cost of a single 
dose was assumed equal for PFS and V&S. Appointment times were obtained from 
a survey of 200 nurses, which estimated that PFS saved on average 4 minutes 47 
seconds relative to V&S across three doses. All unit costs were sourced from the 
literature. Results: The introduction of PFS was estimated to save £7.91 per 3-dose 
primary course and £6,214,562 per year for the NHS. Reductions in wastage and 
staff time contributed the greatest savings. Varying the wastage rate from 1-10% 
resulted in total cost savings of £3-8million; investigation into better estimates 
of vial wastage would strengthen the results. All other sensitivity analyses had 
a minimal impact on results. ConClusions: The switch to PFS administration 
is estimated to have generated substantial cost-savings to the NHS. PFS has the 
potential to improve the efficiency of immunisation programmes by simplifying 
vaccine delivery and reducing the risk of handling errors.
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objeCtives: To assess the cost-effectiveness of pegylated interferons alfa-2a 
and alfa-2b combined with ribavirin in the treatment of Russian patients with 
chronic hepatitis C and identify potential budget impact considering the indica-
tor of rational drug use (IRDU). Methods: The pharmacoeconomic model was 
developed based on the data from randomized controlled trial MIST (M. Rumi 
et al., 2010). The cost-effectiveness ratios (CERs) for different patient subgroups 
were expressed as costs of medicines per one patient with sustained virologic 
response. 24- and 48-week time frames were used for patients with genotypes 2/3 
and 1/4, respectively. To assess quantitatively the impact of pharmaceutical form 
and recommended dose regimens, the IRDU was used. One-way sensitivity analy-
ses (SAs) were performed to investigate the robustness of the cost-effectiveness 
